(Q86454212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Running interference to lower cholesterol (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

John R Burnett

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Amanda J Hooper

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

English

0 references

publication date

3 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

9911

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

10-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

1 reference

7 January 2021

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961910-8

7 January 2021

10.1016/S0140-6736(13)61910-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24094769%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference